Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dr. Lal PathLabsNSE:LALPATHLAB -0.21%93 EBITDA Margin % is 35.03% as of Jun. 2026, which is 18% above its 10-year median of 29.67. GuruFocus rates NSE:LALPATHLAB with a GF Score™ of 93/100 and a GF Value™ of ₹1,735.83 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Dr. Lal PathLabs ranks better than 91.13% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Dr. Lal PathLabs's EBITDA for the
three
months ended in Jun. 2026 was ₹2,794 Mil. Dr. Lal PathLabs's Revenue for the
three
months ended in Jun. 2026 was ₹7,977 Mil. Therefore, Dr. Lal PathLabs's EBITDA margin for the quarter that ended in Jun. 2026 was 35.03%.
Dr. Lal PathLabs (NSE:LALPATHLAB) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Dr. Lal PathLabs EBITDA Margin % Related Terms
Dr. Lal PathLabs EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Dr. Lal PathLabs's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:LALPATHLAB vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Dr. Lal PathLabs's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr. Lal PathLabs EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Dr. Lal PathLabs's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Dr. Lal PathLabs's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr. Lal PathLabs (NSE:LALPATHLAB) has a EBITDA Margin % of 35.03% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Dr. Lal PathLabs and its competitors. This is 18% above median its historical median of 29.67. Over the past decade, Dr. Lal PathLabs' EBITDA Margin % has ranged from 26.36 to 32.06. According to the industry distribution chart, Dr. Lal PathLabs ranks #18 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 8.9%.
Is Dr. Lal PathLabs' EBITDA Margin % too high?
Dr. Lal PathLabs' current EBITDA Margin % of 35.03% is 18% above median its 10-year median of 29.67. Over the past 10 years, this metric has ranged from a low of 26.36 to a high of 32.06. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.00. Dr. Lal PathLabs' value of 35.03% is 600.6% above this industry median. Based on the distribution chart, Dr. Lal PathLabs ranks #18 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Dr. Lal PathLabs has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dr. Lal PathLabs' EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Dr. Lal PathLabs ranks #18 out of 203 companies for EBITDA Margin %. This places Dr. Lal PathLabs in the top 9% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.00. Dr. Lal PathLabs' value of 35.03% is 600.6% above this benchmark. Historically, Dr. Lal PathLabs' own EBITDA Margin % has ranged from 26.36 to 32.06 over the past decade. While the company's 10-year median is 29.67 vs. the industry median of 5.00, Dr. Lal PathLabs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dr. Lal PathLabs's current EBITDA Margin % of 35.03% is 600.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Dr. Lal PathLabs and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dr. Lal PathLabs's current EBITDA Margin % is 35.03%, which is 18% above median its own 10-year median of 29.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr. Lal PathLabs stock overvalued right now?
Based on GuruFocus' analysis, Dr. Lal PathLabs (NSE:LALPATHLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,735.83, compared to a current price of ₹1,949.90 — trading 12.3% above its estimated fair value. The current EBITDA Margin % is 35.03%, which is 18% above median its 10-year median of 29.67 and 600.6% above the Medical Diagnostics & Research industry median of 5.00. Dr. Lal PathLabs' overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Dr. Lal PathLabs (NSE:LALPATHLAB), the current EBITDA Margin % is 35.03% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Dr. Lal PathLabs stock appears to be overvalued.
The current stock price of ₹1,949.90 is trading 12.3% above its estimated GF Value™ of ₹1,735.83.
GuruFocus considers Dr. Lal PathLabs to be Modestly Overvalued.
Key valuation signals for NSE:LALPATHLAB:
EBITDA Margin %: 35.03% (18% above median its 10-year median of 29.67)
GF Value™: ₹1,735.83 vs. price of ₹1,949.90 (12.3% above fair value)
Industry Position: 600.6% above the Medical Diagnostics & Research median (#18 of 203)
No single metric tells the full story. See the NSE:LALPATHLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dr. Lal PathLabs Ltd is a pathology lab based in India. It is involved in providing diagnostic services and other healthcare tests in the areas of pathology and radiology. The company operates laboratories for carrying out pathological diagnostic services in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its diagnostic services assist in preventing, monitoring, and treating diseases and improving health conditions. The company has business operations in India and other countries, of which maximum revenue is generated within India.
93GF Score
Get the complete analysis for NSE:LALPATHLAB
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LALPATHLAB has been successfully added to your 
